PATENT CLAIM ANALYSIS

Application Number: 15769308
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-10
Patent Classification: ["514", "339000"]

Abstract:
The present invention provides a pharmaceutical composition for use in treating acute myeloid leukemia (AML) and a method of treating AML in a patient in need thereof. The present invention also provides a method for predicting the sensitivity to the treatment in the patient using gene expression signature.

Claim (Index 26):
A method of predicting sensitivity to MDM2i treatment in a patient suffering from AML comprising,\n determining whether or not the AML has mutant TP53 gene in its genome,\n when the AML has mutant TP53 gene, then the patient is predicted as resistant, and \n when the AML has wild-type TP53 gene, subsequently measuring the expression levels of at least one, at least two, at least three, at least four or all of the 177 signature genes shown in  FIG. 1  in the AML,\n when the AML has a low signature score compared to a predetermined cutoff value, then the patient is predicted as resistant, and \n when the AML has a high signature score compared to the predetermined cutoff value, then the patient is predicted as sensitive.

Metadata:
- Claim Count in Document: 26.0
- Percentile: 91.0
- Lexical Diversity: 1.52941
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['12438944', '13950881', '14560519', '14430635', '15566336']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.736546276407612
- 35 USC 102 Novelty (BERT): 0.5710944727455168
- Combined Prediction Score: 0.7200010960414026
- Mean Citation Score: 388.860316
- Max Citation Score: 521.67804
- Similarity Product: 319.982002120142

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test